LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Pfizer

Затворен

СекторЗдравеопазване

27.73 0.51

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

27.3

Максимум

27.93

Ключови измерители

By Trading Economics

Приходи

-5.2B

-1.6B

Продажби

903M

18B

P/E

Средно за сектора

19.89

121.746

EPS

0.66

Дивидентна доходност

6.32

Марж на печалбата

-9.387

Служители

81,000

EBITDA

-6.6B

-930M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+6.88% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

6.32%

2.26%

Следващи печалби

28.04.2026 г.

Следваща дата на дивидент

6.03.2026 г.

Следваща дата на екс-дивидент

8.05.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

2.2B

154B

Предишно отваряне

27.22

Предишно затваряне

27.73

Настроения в новините

By Acuity

42%

58%

126 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

Pfizer Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.02.2026 г., 12:25 ч. UTC

Печалби

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

20.01.2026 г., 10:40 ч. UTC

Придобивния, сливания и поглъщания

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments -- Update

20.01.2026 г., 07:47 ч. UTC

Придобивния, сливания и поглъщания

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments

10.02.2026 г., 21:51 ч. UTC

Печалби

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10.02.2026 г., 21:17 ч. UTC

Печалби

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

3.02.2026 г., 21:36 ч. UTC

Печалби

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

3.02.2026 г., 19:56 ч. UTC

Печалби

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3.02.2026 г., 19:46 ч. UTC

Печалби

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

3.02.2026 г., 17:35 ч. UTC

Печалби

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3.02.2026 г., 17:30 ч. UTC

Печалби

These Stocks Are Today's Movers: Palantir, PayPal, Novo Nordisk, Pfizer, Merck, AMD, Gartner, and More -- Barrons.com

3.02.2026 г., 13:50 ч. UTC

Печалби

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3.02.2026 г., 13:06 ч. UTC

Печалби

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3.02.2026 г., 12:45 ч. UTC

Печалби

These Stocks Are Today's Movers: Palantir, PayPal, Teradyne, Tesla, Pfizer, AMD, Merck, and More -- Barrons.com

3.02.2026 г., 12:02 ч. UTC

Печалби

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3.02.2026 г., 11:48 ч. UTC

Печалби

Pfizer: About 20 Key Pivotal Study Starts Planned for 2026 >PFE

3.02.2026 г., 11:48 ч. UTC

Печалби

Pfizer: Enters 2026 With Clear Strategic Priorities, Growing Late-Stage Pipeline >PFE

3.02.2026 г., 11:47 ч. UTC

Печалби

Pfizer: Current Financial Guidance Doesn't Anticipate Any Stock Buybacks in 2026 >PFE

3.02.2026 г., 11:46 ч. UTC

Печалби

Pfizer Sees 2026 Adjusted R&D Expenses $10.5B-$11.5B >PFE

3.02.2026 г., 11:45 ч. UTC

Печалби

Pfizer Reaffirms 2026 Guidance >PFE

3.02.2026 г., 11:45 ч. UTC

Печалби

Pfizer 4Q Rev $17.56B >PFE

3.02.2026 г., 11:45 ч. UTC

Печалби

Pfizer Sees FY Adj EPS $2.80-Adj EPS $3.00 >PFE

3.02.2026 г., 11:45 ч. UTC

Печалби

Pfizer 4Q Adj EPS 66c >PFE

3.02.2026 г., 11:45 ч. UTC

Печалби

Pfizer 4Q Loss/Shr 29c >PFE

3.02.2026 г., 11:45 ч. UTC

Печалби

Pfizer 4Q Loss $1.65B >PFE

3.02.2026 г., 11:45 ч. UTC

Печалби

Pfizer Sees FY Rev $59.5B-$62.5B >PFE

3.02.2026 г., 10:41 ч. UTC

Печалби

These Stocks Are Today's Movers: Palantir, Teradyne, Tesla, AMD, NXP Semiconductors, DaVita, and More -- Barrons.com

20.01.2026 г., 07:13 ч. UTC

Придобивния, сливания и поглъщания

GSK PLC: Agreement Simplifies ViiV's Shareholder Structure

20.01.2026 г., 07:13 ч. UTC

Придобивния, сливания и поглъщания

GSK PLC to Get Special Div of $0.250B

20.01.2026 г., 00:21 ч. UTC

Придобивния, сливания и поглъщания

Shionogi to Acquire Additional Shares in ViiV Healthcare for $2.1B

12.01.2026 г., 21:18 ч. UTC

Пазарно говорене

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Pfizer Прогноза

Ценова цел

By TipRanks

6.88% нагоре

12-месечна прогноза

Среден 28.91 USD  6.88%

Висок 35.46 USD

Нисък 25 USD

Според 18 анализатори от Wall Street, предложили 12-месечна ценова цел за Pfizer през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

18 ratings

6

Купи

12

Задържане

0

Продай

Техническа оценка

By Trading Central

22.855 / 23.85Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

126 / 352 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat